Tianjin Pharmaceutical Da Ren Tang Group Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Lei Wang

Chief executive officer

CN¥1.1m

Total compensation

CEO salary percentage	n/a
CEO tenure	1.7yrs
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	2.5yrs

Recent management updates

Recent updates

CEO

Lei Wang (52 yo)

1.7yrs

Tenure

CN¥1,051,300

Compensation

Ms. Lei Wang serves as GM & Executive Director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited. She served as General Manager of Tianjin Zhongxin Pharmaceutical Group Corporation Limited si...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Lei Wang	GM & Executive Director	1.7yrs	CN¥1.05m	no data
Hong Zhou	Executive Director	less than a year	CN¥1.15m	0.0031% CN¥ 88.4k
Min Guo	Executive Director	no data	no data	no data
Yu Zhang	Chief Production Officer	2yrs	CN¥321.50k	no data
Yan Jiao	Secretary to the Board of Directors	no data	CN¥436.80k	0.0013% CN¥ 37.8k
Jian Ma	Chief Financial Officer	less than a year	no data	no data
Mingjie Shang	Executive Director	less than a year	no data	no data

0.8yrs

Average Tenure

52yo

Average Age

Experienced Management: 2TZ's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Lei Wang	GM & Executive Director	no data	CN¥1.05m	no data
Hong Zhou	Executive Director	less than a year	CN¥1.15m	0.0031% CN¥ 88.4k
Min Guo	Executive Director	2.8yrs	no data	no data
Mingjie Shang	Executive Director	less than a year	no data	no data
Yoke Pheng Liew	Independent & Non-Executive Director	3.8yrs	CN¥259.16k	no data
Yuanxia Wang	Chairman of Board of Supervisors	4.3yrs	no data	no data
Qing Li	Independent & Non-Executive Director	2.9yrs	CN¥60.00k	no data
Jianhua Xing	Supervisor	no data	no data	no data
Mingrui Zhang	Non-Executive & Non-Independent Chairman	2.5yrs	no data	no data
Weiwen Mao	Non-Executive Non-Independent Director	1.3yrs	no data	no data
Guat Kwang Yeo	Lead Independent Director	less than a year	no data	no data

2.5yrs

Average Tenure

52yo

Average Age

Experienced Board: 2TZ's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Tianjin Pharmaceutical Da Ren Tang Group Management

Management criteria checks 1/4

Key information

Recent management updates

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, Annual General Meeting, May 15, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Board Changes

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Zhu Haifeng as an Independent and Non-Executive Director

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Mr. Zhu Haifeng as an Independent Director of the Company, as Well as Chairman of Remuneration Committee, and A Member of Each of Audit Committee, the Nomination Committee, and Strategy Committee

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Appoints Ma Jian as Chief Financial Officer

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Executive Changes

Recent updates

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, Annual General Meeting, May 15, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Q1, 2024 Results on Apr 30, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Fiscal Year 2023 Results on Mar 30, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Board Changes

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Zhu Haifeng as an Independent and Non-Executive Director

New minor risk - Profit margin trend

Third quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.34 in 3Q 2022)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Mr. Zhu Haifeng as an Independent Director of the Company, as Well as Chairman of Remuneration Committee, and A Member of Each of Audit Committee, the Nomination Committee, and Strategy Committee

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393) for CNY 87.8 million.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Appoints Ma Jian as Chief Financial Officer

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Provides Earnings Guidance for the Half Year Ended 30 June 2023

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report First Half, 2023 Results on Aug 15, 2023

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Executive Changes

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Approves Final Dividend for the Financial Period Ended 31 December 2022, Payable on or About 6 June 2023

Investor sentiment improves as stock rises 23%

Full year 2022 earnings released: EPS: CN¥1.12 (vs CN¥1.00 in FY 2021)

High number of new directors

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Wong Gang as Independent and Non-Executive Director

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.26 in 3Q 2021)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Zhang as Director

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Appoints Wang Lei as General Manager

Second quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.32 in 2Q 2021)

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Announces Final Dividend for the Financial Period Ended 31 December 2021, to Be Paid on or About 2 June 2022

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Appoints Zhang Yu as Chief Production Officer

First quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.28 in 1Q 2021)

Less than half of directors are independent

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, Annual General Meeting, May 16, 2022

Full year 2021 earnings released

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Recommends to Declare Dividends for the Year Ended 31 December 2021

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.20 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.20 in 2Q 2020)

Investor sentiment improved over the past week

Independent Non-Executive Director has left the company

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.22 in 1Q 2020)

Tianjin Pharmacy Holdings Co., Ltd. completed the acquisition of 31.02% stake in Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (SGX:T14).

Full year 2020 earnings released: EPS CN¥0.86 (vs CN¥0.81 in FY 2019)

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Announces Cessation of Ni Zhenguo as Deputy General Manager

New 90-day high: €0.72

New 90-day high: €0.70

Third quarter 2020 earnings released: EPS CN¥0.20

Third quarter earnings released

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: €0.61

New 90-day low - €0.65

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Declares No Dividend Has for the Half Year Ended June 30, 2020

Earnings released

New 90-day high - €0.81

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to Report First Half, 2020 Results on Aug 15, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age